News and Announcements
Arthritis Relief Plus Completes US FDA Compliance, Receives Government Support & National News Coverage
- Published August 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ARP has developed and patented a novel technology – Acteev® with its lead product – 4Jointz®, a topical botanical cream addressing a significant unmet market need. It is commercial ready for key international markets.
FY 17 Company Achievements:
- Completed US FDA compliance, securing an OTC topical drug classification for 4Jointz
Secured Australian Government support in the first cohort at the RocketSpace LandingPad in San Francisco. - Awarded new Queensland Government Ignite grant.
- Completed production of first commercial pilot batch of 4Jointz in the USA.
- Direct to consumer online sales testing for USA market commenced at www.4jointz.com
- National and regional broadcast news coverage in Australia.
investment opportunity now on offer to accelerate USA market growth and support global market partnering activities.
ABOUT ARTHRITIS RELIEF PLUS
ARP (USA) Pty Ltd has been granted the rights to commercialize 4JOINTZ® in the USA by Arthritis Relief Plus Ltd, an Australian Biotechnology company, which has developed, patented and successfully completed clinical studies of its unique botanical topical (4JOINTZ®) for pain, stiffness and swelling associated with osteoarthritis and other joint conditions.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
